Comparative Pharmacology
Head-to-head clinical analysis: LANSOPRAZOLE versus PREVACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANSOPRAZOLE versus PREVACID.
LANSOPRAZOLE vs PREVACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, preventing the final step of acid production.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
15-30 mg orally once daily; 30 mg IV over 30 minutes once daily (when oral not possible).
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (increased to 3-6 hours in elderly, hepatic impairment).
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateLansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Lansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Renal (14-23% as metabolites); biliary/fecal (major route, ~60% as metabolites and parent drug).
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor
Lansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole."